Label development and the label comprehension study for over-the-counter drugs

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 5, 2003, Pages 406-412

  Brass, Eric P ^a   Weintraub, Michael ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Lash Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOBENZAPRINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; OMEPRAZOLE;

ACADEMIC ACHIEVEMENT; CLINICAL TRIAL; COMORBIDITY; CONSUMER; DISEASE SEVERITY; DROWSINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG UTILIZATION; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL DECISION MAKING; NEPHROTOXICITY; NOTE; OUTCOMES RESEARCH; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK MANAGEMENT; SELF CARE; SYMPTOM; TECHNIQUE;

DRUG LABELING; DRUGS, NON-PRESCRIPTION; HUMANS; UNITED STATES;

EID: 0242288084     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00239-X     Document Type: Note

References (14)

1. Juhl RP. Prescription to over-the-counter switch: a regulatory perspective. Clin Ther 1998;20(Suppl C):C111-7.
2. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345: 810-6.
3. Lipsky MS, Waters T. The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations. Arch Fam Med 1999;8:297-300.
4. Shi CW, Asch SM, Fielder E, Gelberg L, Brook RH, Leake B, et al. Usage patterns of over-the-counter phenazopyridine (pyridium). J Gen Intern Med 2003;18: 281-7.
5. Food and Drug Administration (US). Safety issues related to ASA and NSAIDs. Available from: URL: http:// www.fda.gov/ohrms/dockets/ac/02/ transcripts/3882T2.htm. 2002. Accessed Sept 28, 2003.
6. Food and Drug Administration (US). Safety issues related to acetaminophen. Available from: URL: http:// www.fda.gov/ohrms/dockets/ac/02/ transcripts/3882T1.htm. 2002. Accessed Sept 28, 2003.
7. Food and Drug Administration (US). Joint Meeting of the Nonprescription Drug Advisory Committee and the Arthritis Advisory Committee. Available from: URL: http:// www.fda.gov/ohrms/dockets/ac/99/transcpt/3525t1a.pdf. 1999. Accessed Sept 28, 2003.
8. Food and Drug Administration (US). Joint Meeting of the Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/02/ transcripts/3861T1.htm. 2002. Accessed Sept 28, 2003.
9. Sansgiry SS, Cady PS. An investigative model evaluating how consumers process pictorial information on nonprescription medication labels. Health Mark Q 1997;14:71-90.
10. Sansgiry SS, Cady PS, Sansgiry S. Consumer involvement: effects on information processing from over-the-counter medication labels. Health Mark Q 2001;19:61-78.
11. Ciociola AA, Sirgo MA, Pappa KA, McGuire JA, Fung K. A study of the nonprescription drug consumer's understanding of the ranitidine product label and actual product usage patterns in the treatment of episodic heartburn. Am J Ther 2001;8:387-98.
12. Food and Drug Administration (US). Labeling OTC human drug products using a column format. Available from: URL: http://www.fda.gov/cder/guidance/ 3594 FNL.PDF. 2000. Accessed Sept 28, 2003.
13. Sansgiry SS, Cady PS, Patil S. Readability of over-the-counter medication labels. J Am Pharm Assoc (Wash) 1997;NS37:522-8.
14. Raymond EG, Dalebout SM, Camp SI. Comprehension of a prototype over-the-counter label for an emergency contraceptive pill product. Obstet Gynecol 2002;100: 342-9.